Compare ANAB & WLFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANAB | WLFC |
|---|---|---|
| Founded | 2005 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2015 | 1997 |
| Metric | ANAB | WLFC |
|---|---|---|
| Price | $63.15 | $223.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | $71.67 | ★ $160.00 |
| AVG Volume (30 Days) | ★ 485.4K | 109.6K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.86% |
| EPS Growth | 91.02 | ★ 146.23 |
| EPS | N/A | ★ 3.26 |
| Revenue | $234,603,000.00 | ★ $569,223,000.00 |
| Revenue This Year | N/A | $2.75 |
| Revenue Next Year | $52.14 | $7.35 |
| P/E Ratio | ★ N/A | $68.26 |
| Revenue Growth | ★ 157.01 | 36.00 |
| 52 Week Low | $17.11 | $114.01 |
| 52 Week High | $73.30 | $239.44 |
| Indicator | ANAB | WLFC |
|---|---|---|
| Relative Strength Index (RSI) | 59.71 | 73.67 |
| Support Level | $52.32 | $165.65 |
| Resistance Level | $67.69 | $239.44 |
| Average True Range (ATR) | 3.05 | 9.35 |
| MACD | 0.99 | 4.46 |
| Stochastic Oscillator | 93.72 | 91.23 |
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum Lease rent revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.